Generic Atrovent HFA Availability
Last updated on Nov 6, 2024.
Atrovent HFA is a brand name of ipratropium, approved by the FDA in the following formulation(s):
ATROVENT HFA (ipratropium bromide - aerosol, metered;inhalation)
-
Manufacturer: BOEHRINGER INGELHEIM
Approval date: November 27, 2004
Strength(s): 0.021MG/INH [RLD]
Has a generic version of Atrovent HFA been approved?
No. There is currently no therapeutically equivalent version of Atrovent HFA available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atrovent HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Inhaler device
Patent 8,474,447
Issued: July 2, 2013
Inventor(s): Von Schuckmann Alfred & Hochrainer Dieter & Hoelz Hubert
Assignee(s): Boehringer Ingelheim International GmbHThe invention relates to a hand-held device (), as depicted in exemplary FIG. , for metered dispensing of sprayable substances, particularly medicaments for inhalation, with a cartridge () that can be moved into the dispensing position, by pressure being applied to a housing, and with a step-by-step indexing mechanism () which is entrained by the cartridge () in the opening travel thereof and which is used to record and display the dispensing actuations that have been performed. In order to suitably design a hand-held device of the type in question with a simplified structure, in such a way that the indexing steps can be performed smoothly and safely without connection to the cartridge, it is proposed that slits () extend obliquely only over part of the travel of the step-by-step indexing mechanism housing () and that the guide pins () guided therein move, over the remainder of the travel of the step-by-step indexing mechanism (), parallel to the longitudinal axis (x-x) of the step-by-step indexing mechanism.
Patent expiration dates:
- January 17, 2030✓
- January 17, 2030
More about Atrovent HFA (ipratropium)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Side effects
- Dosage information
- During pregnancy
- Drug class: anticholinergic bronchodilators
- Breastfeeding
- En español
Patient resources
Other brands
Ipratropium Inhalation Solution, Ipratropium Inhalation Aerosol
Professional resources
Other formulations
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.